Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Insights into the management of Bing-Neel syndrome

Jahanzaib Khwaja • 10 Jun 2022
EHA 2022
Bing-Neel Syndrome Rare Diseases Cytarabine Methotrexate

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, talks on the management of Bing-Neel syndrome (BNS), emphasizing the importance of individualizing treatment in these patients. There is currently no prospective data evaluating therapies in BNS. Therefore, clinicians make treatment decisions based on data from small retrospective studies. Treatment options currently include methotrexate-cytarabine-based therapies as well as less intensive options and BTK inhibitors. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jahanzaib Khwaja

Real-world outcomes of patients with cold agglutinin disease
2:15
Real-world outcomes of patients with cold agglutinin disease
Jahanzaib Khwaja • 8 Dec 2025
A new validated staging system for AL amyloidosis: identifying ultra-high-risk disease
1:46
A new validated staging system for AL amyloidosis: identifying ultra-high-risk disease
Jahanzaib Khwaja • 8 Dec 2025
Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!
1:59
Top amyloidosis updates from ASH 2025: the AQUARIUS trial, CAR T-cells, bispecifics & more!
Jahanzaib Khwaja • 8 Dec 2025
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
1:48
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals